Domestic iodized alcohol market more than 1 billion yuan, the future import replacement can be

"
Pharmaceutical Network Market Analysis" May 22, the domestic iodine contrast agentraw materialsleading Shi Taili issued a notice that the wholly-owned subsidiary Shanghai Steli Pharmaceutical Co., Ltdreceived the Approval of the State Drug Administration approved the issuance of iodidol injection "drug registration approval", and as a consistent evaluationUp to now, the drug's cumulative research and development investment totaled 11.5622 million yuanThe approval of the variety means that its cooperation with Hengrui Pharmaceuticals has entered a substantive stage, and the follow-up is expected to rely on Hengrui's strong sales capacity to achieve import substitution, and is expected to bring a more obvious profit increase for the companyit is learned that Stely and its wholly-owned subsidiary, Shanghai Staili, signed a drug cooperation agreement with Hengrui Pharmaceuticals, the domestic leader of iodine contrast agent preparations, on May 11, 2020According to the agreement, Sterie will be responsible for the development and registration of cooperative products (iodized sea alcohol injections and iodidaol injections) that meet the requirements of the relevant drug regulatory authorities in NMPA or other fields, while Hengrui Pharma will be responsible for the commercial operation of the cooperative products, including marketing, self-marketing, self-sales or in cooperation with distributorsBoth sides according to the product sales gross margin of 55 divided, Hengrui Pharmaceuticals for each Division Of The approved listed preparation products to pay 5 million yuanmeters net data show that in 2019 China's public medical institutions terminal contrast agent sales of 15.210 billion yuan, sales of more than 1 billion yuan of brands have 7Iodaol is the main preparation in the field of contrast agents, developed by the Italian company Bracco (Boleco), as a monomer non-ionic contrast agent, the toxicity to blood vessels and nerves are low, local and systemic tolerance is better, permeability is low, the injection is also stableAccording to the Newport Premium database, the global X-ray contrast agent market will be about $4,042 million in 2018, with iodol being about $685 million, with the main market for applications being in the United States and EuropeThe domestic iodol market is also very largeAccording to the China Pharmaceutical Industry Information Center, the domestic X-ray contrast agent market in 2019 will be about 13.945 billion yuan, of which the market size of iodol is about 1.513 billion yuan is worth noting that the current iodaol market only the original research Bracco, Shanghai Boleko Xinyi Pharmaceutical Co., Ltd., Beilu Pharmaceutical, Kangchen Pharmaceuticals 4 participants In addition, 2019 sample hospital data show that the proportion of iodine paol primary research Bracco as high as more than 90%, other domestic pharmaceutical companies accounted for a relatively small proportion With the approval of the iodized alcohol injection of Steli, or further distribution with the original Research Bracco food market, iodol import alternative period it is understood that, in addition to the approved listing of iodized alcohol injection, there are iodine sea alcohol injection, iodide saol injection, iodine fool injection, iodine meepol injection four iodine contrast agent formulation varieties have been in the different stages of preparation declaration, of which iodide sea alcohol and iodized saol progress faster With the successful approval of iodol experience, the enterprise may speed up the approval of follow-up formulation varieties industry believes that in the past, imaging radiation in the discipline is a "follow-up policy", domestic enterprises are not innovative, almost with imitation drugs instead of imported drugs, this application to a large extent reduce costs At present, the domestic market is booming, the global market contrast agent original research alternative space is broad With the imaging drug "domestic" after the price has also become friendly, will bring more choices for domestic patients.